Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 1.73 below Insight Molecular Diagnostics Inc 's average Quick Ratio.

Within In Vitro & In Vivo Diagnostic Substances industry 7 other companies have achieved higher Quick Ratio than Insight Molecular Diagnostics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1015 to 1356.

Explain Quick Ratio?
How much Cash & cash equivalents IMDX�s has?
What are IMDX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IMDX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	54.63 %	23.98 %	-8.95 %	-15.73 %	-7.59 %
Y / Y Cash & cash equivalent Change	-26.89 %	-9.11 %	34.12 %	455.81 %	162.39 %
Quick Ratio MRQ	1.73	2.35	1.65	2.44	3.65
IMDX's Total Ranking	# 1356	# 1015	# 866	# 513	#
Seq. Current Liabilities Change	-14.32 %	70.7 %	-8.19 %	15.15 %	-31.3 %
Seq. Cash & cash equivalent Change	-37.04 %	143.47 %	-38.03 %	-23.04 %	-21.73 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 8
Healthcare Sector	# 525
Overall Market	# 1356

Quick Ratio Statistics
High	Average	Low
13.18	3.54	0.37
(Sep 30 2016)		(Sep 30 2024)

Financial Statements
Insight Molecular Diagnostics Inc 's Current Liabilities	$ 10 Millions	Visit IMDX's Balance sheet
Insight Molecular Diagnostics Inc 's Cash & cash equivalent	$ 18 Millions	Visit IMDX's Balance sheet
Source of IMDX's Sales		Visit IMDX's Sales by Geography

Cumulative Insight Molecular Diagnostics Inc 's Quick Ratio

IMDX's Quick Ratio for the trailling 12 Months

IMDX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	11.57 %	-1.02 %	-4.05 %	7.31 %	16.31 %
Y / Y Cash & cash equivalent TTM Growth	13.25 %	58.3 %	218.98 %	199.12 %	76.92 %
Quick Ratio TTM	2.06	2.48	2.76	2.61	2.03
Total Ranking TTM	# 3841	# 3000	# 2897	# 2112	#
Seq. Current Liabilities TTM Growth	10.9 %	7.48 %	-2.18 %	-4.31 %	-1.62 %
Seq. Cash & cash equivalent TTM Growth	-7.89 %	-3.3 %	3.57 %	22.77 %	28.75 %

Quick ratio ranking by company, industry and sector >> Back to IMDX Financial Strength Comparisons >> Go to Compare IMDX Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q2 2026 to $10.29 millions, cumulative Quick Ratio decreased to 2.06 below the Insight Molecular Diagnostics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Insight Molecular Diagnostics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3000 to 3841.

Explain Quick Ratio?
How much Cash & cash equivalents IMDX�s has?
What are IMDX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 885
Within the Market	# 3841

trailing twelve months Quick Ratio Statistics
High	Average	Low
7.91	2.63	0.84
(Dec 31 2019)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Qc Technologies Inc	3.00	$ 10.987 Millions	$ 3.669 Millions
Alpha Teknova Inc	2.54	$ 17.436 Millions	$ 6.872 Millions
Lantheus Holdings Inc	1.77	$ 593.298 Millions	$ 335.677 Millions
Insight Molecular Diagnostics Inc	1.73	$ 17.756 Millions	$ 10.286 Millions
Achieve Life Sciences Inc	1.65	$ 326.645 Millions	$ 197.657 Millions
Immucell Corporation	1.51	$ 8.860 Millions	$ 5.863 Millions
Myriad Genetics Inc	0.88	$ 115.200 Millions	$ 130.700 Millions
Biomerica Inc	0.53	$ 1.308 Millions	$ 2.481 Millions

Date modified: 2026-08-12T20:15:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.